Advik Laboratories share news and announcements
BSE: 531686Pharmaceuticals & BiotechnologySmall Cap
Last close ₹2.08₹0.00 (0.00%)
Share price at the BSE close on 19 Oct 2026. Previous close ₹2.08.
52-week range of traded prices to 19 Oct 2026
₹1.57Low, 2 Mar 2026₹2.08High, 15 Sep 2026
- Under BSE's graded surveillance, stage IV, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹3.98 Cr5,167th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 28 May 2026
- 58.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 13 Aug 2026
- −180.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- −14.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 28 May 2026
- 109.84
- Volume, BSEVolume. Shares traded on the last trading day.
- 300
Advik Laboratories routine notices
147 filed, newest first. Page 3 of 3.
Dec 2019
Nov 2019
Sep 2019
Aug 2019
Jun 2019
May 2019
Apr 2019
Feb 2019
Nov 2018
Oct 2018
Sep 2018
Aug 2018
May 2018
Feb 2018
Dec 2017
Sep 2017
May 2017
Feb 2017
Nov 2016
Sep 2016
Aug 2016
May 2016
17 May · Routine
Meeting of the Board of Directors of the company is scheduled to be held on May 30, 2016 inter alia, to consider and approve the Audited Financial ....
Feb 2016
5 Feb · Routine
Meeting of the Board of Directors of the Company will be held on February 13, 2016, inter alia, to transact the following businesses: ....
Nov 2015
4 Nov · Routine
Meeting of the Board of Directors of the Company is scheduled to be held on November 14, 2015, inter alia, to consider and approve the Unaudited ....
May 2015
19 May · Routine
Meeting of the Board of Directors of the company is scheduled to be held on May 30, 2015, inter-alia, to consider and approve the Audited ....